Bortezomib plus low dose cytarabine in Int-2 and high risk MDS. Interim results of a phase I/II trial by the GFM

被引：0
|
作者：
Natarajan, Shahti [1 ]
Fenaux, Pierre [1 ]
Vey, Norbert [1 ]
Guerci, A. [1 ]
Coulibaly, I. [1 ]
Charbonnier, A. [1 ]
Ravoet, C. [1 ]
Courby, S. [1 ]
Etienne, G. [1 ]
Chaury, M. P. [1 ]
Cheze, S. [1 ]
Stamatoullas, A. [1 ]
Legros, L. [1 ]
Berger, E. [1 ]
Lescoute, A. [1 ]
Vaultier, S. [1 ]
Dreyfus, F. [1 ]
机构：
[1] Grp Francophone Myelodysplasies, Paris, France
来源：
BLOOD | 2007年 / 110卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1453
引用
收藏
页码：435A / 435A
页数：1
相关论文
共 50 条
  • [21] Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Final Results of a Phase I/II Trial
    Richardson, Paul G.
    Wolf, Jeffrey Lee
    Jakubowiak, Andrzej J.
    Zonder, Jeffrey A.
    Lonial, Sagar
    Irwin, David
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur S.
    Bar, Michael H.
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Martin, Thomas
    Laubach, Jacob P.
    Allerton, Jeffrey P.
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    BLOOD, 2011, 118 (21) : 371 - 371
  • [22] Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
    Richardson, Paul G.
    Wolf, Jeff
    Jakubowiak, Andrzej
    Zonder, Jeff
    Lonial, Sagar
    Irwin, David
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur
    Bar, Michael
    Martin, Tom
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil
    Laubach, Jacob
    Allerton, Jeff
    Hideshima, Teru
    Colson, Kathleen
    Poradosu, Enrique
    Gardner, Lesa
    Sportelli, Peter
    Anderson, Kenneth C.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) : 4243 - 4249
  • [23] 5-AZACYTIDINE, VALPROIC ACID AND ALL-TRANS RETINOIC ACID IN INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES: FIRST RESULTS OF THE GIMEMA MDS0205 MULTICENTER TRIAL
    Voso, M. T.
    Santini, V
    Finelli, C.
    Borin, L.
    Angelucci, E.
    Fioritoni, G.
    Neri, B.
    Cortelezzi, A.
    Villani, O.
    Zini, G.
    Petti, M. C.
    Martinelli, G.
    Fazi, P.
    Piciocchi, A.
    Gobbi, M.
    Foa, R.
    Amadori, S.
    Liso, V
    Leone, G.
    HAEMATOLOGICA, 2008, 93 : S77 - S77
  • [24] A phase II trial of bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma (MCL) (CALGB 50501): Results of a planned interim analysis
    Morrison, V. A.
    Johnson, J. L.
    Jung, S.
    Leonard, J. P.
    Cheson, B. D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [25] Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS)
    Oliva, Esther Natalie
    Riva, Marta
    Niscola, Pasquale
    Santini, Valeria
    Breccia, Massimo
    Giai, Valentina
    Poloni, Antonella
    Patriarca, Andrea
    Crisa, Elena
    Capodanno, Isabella
    Salutari, Prassede
    Reda, Gianluigi
    Cascavilla, Nicola
    Ferrero, Dario
    Guarini, Attilio
    Tripepi, Giovanni
    Ianni, Giuseppe
    Russo, Emilio
    Castelli, Andrea
    Fattizzo, Bruno
    Beltrami, Germana
    Bocchia, Monica
    Molteni, Alfredo
    Fenaux, Pierre
    Germing, Ulrich
    Ricco, Alessandra
    Palumbo, Giuseppe A.
    Impera, Stefana
    Di Renzo, Nicola
    Rivellini, Flavia
    Buccisano, Francesco
    Stamatoullas-Bastard, Aspasia
    Liberati, Anna Marina
    Candoni, Anna
    Delfino, Ilaria Maria
    Arcadi, Maria Teresa
    Cufari, Patrizia
    Rizzo, Lorenzo
    Bova, Irene
    D'Errigo, Maria Grazia
    Zini, Gina
    Latagliata, Roberto
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (28) : 4486 - +
  • [26] UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Montalban-Bravo, G.
    Prithviraj, B.
    Alvarado, Y.
    Daver, N.
    Ravandi, F.
    Borthakur, G.
    Takahashi, K.
    Andreeff, M.
    Cortes, J.
    DiNardo, C.
    Jabbour, E.
    Kadia, T.
    Kornblau, S.
    Ohanian, M.
    Nogueras-Gonzalez, G. M.
    Bodden, K.
    Pierce, S.
    Kantarjian, H.
    Garcia-Manero, G.
    LEUKEMIA RESEARCH, 2017, 55 : S25 - S26
  • [27] Tipifarnib (ZARNESTRA™) in previously untreated poor-risk AML and MDS:: Interim results of a phase 2 trial.
    Lancet, JE
    Gojo, I
    Gotlib, J
    Greer, J
    Kaufmann, SH
    Liesveld, JL
    Adjei, A
    Messina, P
    Dugan, K
    Bruzek, L
    Lu, CH
    Thibault, A
    Rybak, ME
    Rackoff, W
    Wright, JJ
    Greenberg, PL
    Karp, JE
    BLOOD, 2003, 102 (11) : 176A - 176A
  • [28] ORAL CLOFARABINE PLUS LOW-DOSE CYTARABINE IN PREVIOUSLY TREATED AML AND HIGH-RISK MDS PATIENTS=60 YEARS OF AGE
    Pagel, M.
    Sandhu, R.
    Gooley, T.
    Scott, B.
    Shannon-Dorcy, K.
    Dean, C.
    Appelbaum, R.
    Estey, H.
    HAEMATOLOGICA, 2012, 97 : 29 - 29
  • [29] UPDATED RESULTS FROM PHASE 2 STUDY OF GUADECITABINE FOR PATIENTS WITH UNTREATED INT-2/HIGH RISK MYELODYSPLASTIC SYNDROMES OR CHRONIC MYELOMONOCYTIC LEUKEMIA
    Montalban-Bravo, G.
    Bose, P.
    Alvarado, Y.
    Daver, N.
    Ravandi, F.
    Borthakur, G.
    Takahashi, K.
    Andreeff, M.
    Cortes, J.
    DiNardo, C.
    Jabbour, E. J.
    Kadia, T.
    Kornblau, S.
    Ohanian, M.
    Alfonso, A.
    Huang, X.
    Nogueras Gonzalez, G.
    Bodden, K.
    Pierce, S.
    Bueso-Ramos, C.
    Kantarjian, H.
    Garcia-Manero, G.
    HAEMATOLOGICA, 2017, 102 : 99 - 99
  • [30] A phase I/II trial of bortezomib, low dose intravenous melphalan and dexamethasone for patients with relapsed multiple myeloma.
    Popat, Rakesh
    Williams, Catherine
    Cook, Mark
    Craddock, Charles
    Basu, Supratik
    Singer, Charles
    Odeh, Liz
    Foot, Nicola
    Oakervee, Heather
    Cavenagh, James D.
    BLOOD, 2006, 108 (11) : 1011A - 1011A
12345